FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

Check this box if no longer subject to	
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPRO	VAL
OMB Number:	3235-0287
Estimated average burd	en
hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>El-Hibri Fuad</u>						2. Issuer Name and Ticker or Trading Symbol Emergent BioSolutions Inc. [EBS]									S. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner						
(Last) (First) (Middle) 2273 RESEARCH BLVD., SUITE 400						3. Date of Earliest Transaction (Month/Day/Year) 03/08/2013									X Officer (give title Other (specification) below) Chairman						
(Street) ROCKVILLE MD 20850 (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year) 03/12/2013									6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
		Tabl	e I - No	n-Deri\	ative	Se	curitie	s Ac	quired,	Dis	posed o	f, o	r Ben	efici	ally	Owne	ed				
District of Goodinity (motified)				Date	2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4			(A) or 3, 4 ar	and 5) Secur Benef Owne		icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount		(A) or (D)	Price	Price		Reported Transaction(s) (Instr. 3 and 4)			(111501.4)	
Common Stock				03/08/2013		T			F		3,818		D	\$15.22		1,841,752(1)		D			
Common Stock 03/12					/2013				F		1,463		D	D \$14.		.67 1,840,289(2)		D			
Common Stock 03/12					/2013				A		20,9020	(3)	A	A \$0		1,861,191(4)		D ⁽⁵⁾			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/D	n Date,	4. Transa Code (8)	of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			6. Date Expiration (Month/L	on Dat		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4) Amoun or Numbe of Title Shares		ount	ıt r		9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Owner Form Direct or Inc (I) (In		11. Nature of Indirect Beneficial Ownership (Instr. 4)	

Explanation of Responses:

- 1. This amendment on Form 4/A is being filed to correct an overstatement of 590 shares in the amount of securities disposed of by the reporting person and to correct the resulting amount of securities beneficially owned by the reporting person following such disposition. Except as described in footnotes 2 and 4, there are no other changes from the information originally reported on the Form 4 as originally
- 2. This amendment on Form 4/A is being filed to correct an overstatement of 254 shares in the amount of securities disposed of by the reporting person and to correct the resulting amount of securities beneficially owned by the reporting person following such disposition. Except as described in footnotes 1 and 4, there are no other changes from the information originally reported on the Form 4 as originally filed on March 12, 2013.
- 3. These restricted stock units vest in three equal annual installments beginning on the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
- 4. Adjusted to reflect the correct total number of securities beneficially owned by the reporting person after giving effect to the corrections described in footnotes 1 and 2. Except as described in footnotes 1 and 2, there are no other changes from the information originally reported on the Form 4 as originally filed on March 12, 2013.
- 5. Mr. El-Hibri's direct holdings include restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan.

/s/ Carl A. Valenstein, attorney-04/18/2013 in-fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.